InterCure (INCR) Competitors $1.56 -0.05 (-2.81%) Closing price 05/21/2025 03:57 PM EasternExtended Trading$1.55 0.00 (-0.32%) As of 08:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INCR vs. ACB, CADL, NGNE, RNAC, TSVT, ALMS, INZY, GLUE, TERN, and PVLAShould you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Aurora Cannabis (ACB), Candel Therapeutics (CADL), Neurogene (NGNE), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Alumis (ALMS), Inozyme Pharma (INZY), Monte Rosa Therapeutics (GLUE), Terns Pharmaceuticals (TERN), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. InterCure vs. Aurora Cannabis Candel Therapeutics Neurogene Cartesian Therapeutics 2seventy bio Alumis Inozyme Pharma Monte Rosa Therapeutics Terns Pharmaceuticals Palvella Therapeutics Aurora Cannabis (NASDAQ:ACB) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Does the media prefer ACB or INCR? In the previous week, Aurora Cannabis had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for Aurora Cannabis and 0 mentions for InterCure. Aurora Cannabis' average media sentiment score of 0.81 beat InterCure's score of 0.75 indicating that Aurora Cannabis is being referred to more favorably in the media. Company Overall Sentiment Aurora Cannabis Positive InterCure Positive Do institutionals & insiders have more ownership in ACB or INCR? 47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 0.2% of InterCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend ACB or INCR? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ACB or INCR more profitable? Aurora Cannabis has a net margin of 0.42% compared to InterCure's net margin of 0.00%. Aurora Cannabis' return on equity of 0.59% beat InterCure's return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis0.42% 0.59% 0.42% InterCure N/A N/A N/A Does the MarketBeat Community believe in ACB or INCR? Aurora Cannabis received 381 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote. CompanyUnderperformOutperformAurora CannabisOutperform Votes38459.63% Underperform Votes26040.37% InterCureOutperform Votes3100.00% Underperform VotesNo Votes Which has more risk and volatility, ACB or INCR? Aurora Cannabis has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Which has stronger earnings and valuation, ACB or INCR? InterCure has lower revenue, but higher earnings than Aurora Cannabis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$320.81M0.91-$48.62M$0.05104.40InterCure$238.85M0.30-$16.83MN/AN/A SummaryAurora Cannabis beats InterCure on 13 of the 16 factors compared between the two stocks. Get InterCure News Delivered to You Automatically Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCR vs. The Competition Export to ExcelMetricInterCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.87M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / Sales0.30253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.576.466.794.50Net Income-$16.83M$143.98M$3.23B$248.18M7 Day Performance2.98%2.03%1.53%0.20%1 Month Performance12.68%4.11%10.06%12.37%1 Year Performance-49.84%-2.87%16.72%7.04% InterCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCRInterCure0.7232 of 5 stars$1.56-2.8%N/A-52.9%$70.87M$238.85M0.00350Gap DownACBAurora Cannabis0.6157 of 5 stars$5.02-2.1%N/A-26.8%$282.19M$320.81M100.421,340CADLCandel Therapeutics2.0276 of 5 stars$5.70+6.5%$21.00+268.4%-55.4%$280.84M$120,000.00-3.2960Gap UpNGNENeurogene2.5223 of 5 stars$19.52+8.5%$43.40+122.3%-46.2%$278.39M$925,000.00-4.4990Analyst ForecastGap UpRNACCartesian Therapeutics1.5386 of 5 stars$10.37+1.1%$42.50+309.8%-62.3%$269.14M$34.17M-0.2064News CoverageAnalyst RevisionGap UpTSVT2seventy bio1.5487 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$48.37M-2.69440Positive NewsALMSAlumis2.193 of 5 stars$5.95+5.9%$24.86+317.8%N/A$265.38MN/A0.00N/AINZYInozyme Pharma2.8857 of 5 stars$3.99+1.0%$11.75+194.5%-16.0%$257.60MN/A-2.5650High Trading VolumeGLUEMonte Rosa Therapeutics2.1802 of 5 stars$4.11+3.3%$15.50+277.1%-6.6%$252.81M$159.49M-2.2590Positive NewsTERNTerns Pharmaceuticals4.0973 of 5 stars$3.15+9.4%$15.63+396.0%-51.1%$251.53MN/A-2.6740News CoveragePositive NewsGap DownPVLAPalvella Therapeutics3.7987 of 5 stars$22.56+2.3%$46.29+105.2%N/A$249.13M$42.81M-1.86N/AEarnings ReportAnalyst Revision Related Companies and Tools Related Companies ACB Competitors CADL Competitors NGNE Competitors RNAC Competitors TSVT Competitors ALMS Competitors INZY Competitors GLUE Competitors TERN Competitors PVLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INCR Stock Free INCR Stock Alerts